As companies struggle with declining productivity in research and development (R&D), they are increasingly looking for markers that could distinguish between commercial success and failure for those drugs that do reach the market. Given that it is common for several companies to be simultaneously pursuing promising new targets, one fundamental question is whether it is better to be first or best in a particular new class of drugs.
展开▼
